Stereotaxis, Inc. (NYSEAMERICAN:STXS) Director Acquires $68,780.00 in Stock

Stereotaxis, Inc. (NYSEAMERICAN:STXS) Director Paul J. Isaac acquired 38,000 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were acquired at an average cost of $1.81 per share, for a total transaction of $68,780.00. Following the acquisition, the director now directly owns 87,299 shares of the company’s stock, valued at $158,011.19. This trade represents a 77.08 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Stereotaxis Price Performance

Shares of STXS stock opened at $1.83 on Thursday. The business’s fifty day simple moving average is $2.24. Stereotaxis, Inc. has a 1-year low of $1.66 and a 1-year high of $3.29. The firm has a market capitalization of $155.06 million, a price-to-earnings ratio of -6.54 and a beta of 1.54.

Institutional Trading of Stereotaxis

Several large investors have recently bought and sold shares of STXS. Lagoda Investment Management L.P. grew its holdings in Stereotaxis by 7.7% in the fourth quarter. Lagoda Investment Management L.P. now owns 4,126,135 shares of the company’s stock valued at $9,408,000 after purchasing an additional 295,700 shares during the last quarter. Traynor Capital Management Inc. acquired a new stake in Stereotaxis in the fourth quarter valued at $366,000. JPMorgan Chase & Co. grew its holdings in Stereotaxis by 463.8% in the fourth quarter. JPMorgan Chase & Co. now owns 134,822 shares of the company’s stock valued at $307,000 after purchasing an additional 110,909 shares during the last quarter. Diametric Capital LP acquired a new stake in Stereotaxis in the fourth quarter valued at $217,000. Finally, Geode Capital Management LLC boosted its stake in shares of Stereotaxis by 7.2% during the third quarter. Geode Capital Management LLC now owns 1,391,718 shares of the company’s stock valued at $2,840,000 after acquiring an additional 93,253 shares during the last quarter. Institutional investors and hedge funds own 45.35% of the company’s stock.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.